Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) Meeting Abstract
| Authors: | Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A. |
| Abstract Title: | Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) |
| Meeting Title: | 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 26 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2008 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2008-05-20 |
| Start Page: | 47s |
| Language: | English |
| ACCESSION: | WOS:000208457400356 |
| DOI: | 10.1200/jco.2008.26.15_suppl.1027 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1027 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
